The Influence of Endogenous Testosterone on Incidental Prostate Cancer after Transurethral Prostate Resection.


Journal

Urologia internationalis
ISSN: 1423-0399
Titre abrégé: Urol Int
Pays: Switzerland
ID NLM: 0417373

Informations de publication

Date de publication:
2021
Historique:
received: 17 09 2020
accepted: 07 01 2021
pubmed: 10 5 2021
medline: 19 1 2022
entrez: 9 5 2021
Statut: ppublish

Résumé

The aim of the study was to test the hypothesis that endogenous total testosterone (TT) may relate to incidental prostate cancer (iPCA) in patients with lower urinary tract symptoms (LUTS) associated with prostate enlargement undergoing transurethral resection of the prostate (TURP). The hypothesis was tested in contemporary cohort of patients who underwent TURP because of LUTS due to prostate enlargement after excluding the suspect of PCA. In period running from January 2017 to November 2019, 389 subjects were evaluated. Endogenous testosterone was measured preoperatively between 8:00 and 10:00 o'clock in the morning. Relationships between TT and iPCA were evaluated by statistical methods. Overall, iPCA was detected in 18 cases (4.6%) with clinical stage cT1a or International Society of Urologic Pathology (ISUP) < 2 in 11 patients (61.1%). Endogenous testosterone was inversely associated with age and BMI in the study population but not in the subgroup with iPCA in wholly endogenous TT strongly correlated to both number of chips involved by cancer (Pearson's correlation coefficient, r = 0.553; p = 0.017) and ISUP > 2 (r = 0.504; p = 0.033). The positive association of endogenous TT with both tumor load and tumor grade was confirmed by the linear regression model with high-regression coefficients for the former (regression coefficient, b = 0.307; 95% confidence interval, 95% CI: 0.062-0.551; and p = 0.017) as for the latter (b = 5.898; 95% CI: 0.546-11.249; and p = 0.033). Preoperative endogenous TT is associated with features of iPCA. The influence of iPCA on endogenous testosterone needs to be addressed by a large multicenter prospective trial.

Identifiants

pubmed: 33965959
pii: 000514391
doi: 10.1159/000514391
doi:

Substances chimiques

Biomarkers 0
Testosterone 3XMK78S47O

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

826-834

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Antonio B Porcaro (AB)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Salvatore Siracusano (S)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Nelia Amigoni (N)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Alessandro Tafuri (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Department of Neuroscience, Imaging and Clinical Sciences, "G. D'Annunzio" University, Chieti, Italy.

Riccardo Rizzetto (R)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Aliasger Shakir (A)

Department of Urology, Keck School of Medicine, USC Institute of Urology and Catherine and Joseph Aresty, University of Southern California (USC), Los Angeles, California, USA.

Leone Tiso (L)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Clara Cerrato (C)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Mario De Michele (M)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Alberto Bianchi (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Sebastian Gallina (S)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Matteo Brunelli (M)

Department of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Filippo Migliorini (F)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Walter Artibani (W)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Alessandro Antonelli (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH